Roccuzzo, G.; Fava, P.; Astrua, C.; Brizio, M.G.; Cavaliere, G.; Bongiovanni, E.; Santaniello, U.; Carpentieri, G.; Cangiolosi, L.; Brondino, C.;
et al. Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma. Cancers 2024, 16, 3095.
https://doi.org/10.3390/cancers16173095
AMA Style
Roccuzzo G, Fava P, Astrua C, Brizio MG, Cavaliere G, Bongiovanni E, Santaniello U, Carpentieri G, Cangiolosi L, Brondino C,
et al. Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma. Cancers. 2024; 16(17):3095.
https://doi.org/10.3390/cancers16173095
Chicago/Turabian Style
Roccuzzo, Gabriele, Paolo Fava, Chiara Astrua, Matteo Giovanni Brizio, Giovanni Cavaliere, Eleonora Bongiovanni, Umberto Santaniello, Giulia Carpentieri, Luca Cangiolosi, Camilla Brondino,
and et al. 2024. "Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma" Cancers 16, no. 17: 3095.
https://doi.org/10.3390/cancers16173095
APA Style
Roccuzzo, G., Fava, P., Astrua, C., Brizio, M. G., Cavaliere, G., Bongiovanni, E., Santaniello, U., Carpentieri, G., Cangiolosi, L., Brondino, C., Pala, V., Ribero, S., & Quaglino, P.
(2024). Real-Life Outcomes of Adjuvant Targeted Therapy and Anti-PD1 Agents in Stage III/IV Resected Melanoma. Cancers, 16(17), 3095.
https://doi.org/10.3390/cancers16173095
